IP Library › Granted Patent US 10,766,915
Granted Patent B2
US 10,766,915 · App. 14/777,169 · Granted Sep 8, 2020

Metal-based coordination complexes as photodynamic compounds and their use

Inventor: Sherri Ann McFarland (Mount Uniacke, CA)
C07F15/0053A61K31/473A61K41/0057C07F15/0026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,766,915
App. No.
14/777,169
Granted
Sep 8, 2020
Kind
B2
Abstract

Compositions of the invention include metal-based coordination complexes, which are preferably tunable photodynamic compounds. The compositions and complexes are useful as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions and complexes of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses. The compositions and complexes are also capable of modulating cell function in other ways.

Claims (26)

1. A compound having the formula (V)

including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

M is selected from the group consisting of osmium, manganese, molybdenum, rhenium, ruthenium, iron, cobalt, rhodium, iridium, nickel, and platinum;

X is selected from the group consisting of Cl − , PF 6 − , Br − , BF 4 − , ClO 4 − , CF 3 SO 3 − , and SO 4 −2 ;

n=0, 1, 2, 3, 4, or 5;

Lig 3 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of

R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , and R 3l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, optionally substituted phenyl, and CO 2 R 8 ;

R 8 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl;

wherein: (a) the compound is not Os(biq) 3 (ClO 4 ) 2 ·H 2 O, where biq is 2,2′-biquinoline, and (b) when M is ruthenium: (i) no more than two substituents on M are identical, and (ii) no more than one substituent on M is 2,2′-biquinoline.

2. A compound having the formula [Os(biq) 2 (Lig)]X n , where:

X is selected from the group consisting of Cl − , PF 6 − , Br − , BF 4 − , ClO 4 − , CF 3 SO 3 − , and SO 4 −2 ;

n=0, 1, 2, 3, 4, or 5;

Lig is a bidentate ligand other than unsubstituted biq selected from the group consisting of

R 1 is selected from the group consisting of hydrogen, optionally substituted phenyl, optionally substituted aryl, optionally substituted heteroaryl, 4-pyridyl, 3-pyridyl, 2-thiazole, 2-pyrolyl, 2-furanyl,

u is an integer;

R 2a , R 2b , R 2c , R 2d , R 2e , R 2f , R 2g , R 2h , R 2i , R 2j , R 2k , and R 2l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 3-7 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , SO 3 H, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle;

R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , and R 3l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, optionally substituted phenyl, and CO 2 R 8 ;

R 4a , R 4b , and R 4c at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle;

R 4a and R 4b at each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms;

R 5 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl;

R 6 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl;

R 7 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl;

R 8 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and

biq is 2,2′-biquinoline.

3. The compound of claim 2 , wherein Lig is 1,10-phenanthroline, imidazo[4,5-f][1,10]phenathroline or benzo[i]dipyrido[3,2-α:2′,3′-c]phenazine.

4. The compound of claim 3 , wherein X is Cl − and n is 2.

Continuity (2)
Provisional Application 61801674 · Mar 15, 2013
Related Publication 20160039854A1 · Feb 11, 2016